Biomaterial Database

Mechanisms of action of intravenous immunoglobulin (IVIG). 2000

M D Kazatchkine, and B Bellon, and S V Kaveri

INSERM U430 and Université Pierre et Marie Curie, H pital Broussais, Paris, France.

Therapeutic preparations of pooled normal polyspecific immunoglobulin G for intravenous use (intravenous immunoglobulin, IVIG) have been shown to be effective in the treatment of a number of autoimmune and systemic inflammatory conditions. IVIG prevents the occurrence of experimental autoimmune encephalomyelitis. Increasing evidence suggests that IVIG is of benefit in patients with relapsing-remitting multiple sclerosis. The present review discusses the immunoregulatory properties and mechanisms of action of IVIG in autoimmune disease.

UI	MeSH Term	Description	Entries
D011961	Receptors, Fc	Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognize and combine with the Fc (crystallizable) portion of immunoglobulin molecules.	Fc Receptors,Fc Receptor,Receptor, Fc
D002455	Cell Division	The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.	M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000906	Antibodies	Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D001327	Autoimmune Diseases	Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	Autoimmune Disease,Disease, Autoimmune,Diseases, Autoimmune
D001402	B-Lymphocytes	Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.	B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent
D013601	T-Lymphocytes	Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.	T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D016756	Immunoglobulins, Intravenous	Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA.	Antibodies, Intravenous,Human Intravenous Immunoglobulin,IV Immunoglobulin,IVIG,Intravenous Antibodies,Intravenous Immunoglobulin,Intravenous Immunoglobulins,Alphaglobin,Endobulin,Flebogamma DIF,Gamimmune,Gamimmune N,Gamimune,Gamimune N,Gammagard,Gammonativ,Gamunex,Globulin-N,IV Immunoglobulins,Immune Globulin Intravenous (Human),Immune Globulin, Intravenous,Immunoglobulins, Intravenous, Human,Intraglobin,Intraglobin F,Intravenous IG,Intravenous Immunoglobulins, Human,Iveegam,Modified Immune Globulin (Anti-Echovirus Antibody),Privigen,Sandoglobulin,Venimmune,Venoglobulin,Venoglobulin-I,Globulin N,Human Intravenous Immunoglobulins,Immunoglobulin, Human Intravenous,Immunoglobulin, IV,Immunoglobulin, Intravenous,Immunoglobulins, Human Intravenous,Immunoglobulins, IV,Intravenous Immune Globulin,Intravenous Immunoglobulin, Human,Venoglobulin I

Related Publications

M D Kazatchkine, and B Bellon, and S V Kaveri

Mechanisms of action of intravenous immunoglobulin (IVIg) in autoimmune and neuromuscular diseases.

January 1999, Electroencephalography and clinical neurophysiology. Supplement,

M D Kazatchkine, and B Bellon, and S V Kaveri

Intravenous immunoglobulin (IVIG).

April 2007, Obstetrics and gynecology,

M D Kazatchkine, and B Bellon, and S V Kaveri

Intravenous immunoglobulin (IVIG).

December 2006, The Medical letter on drugs and therapeutics,

M D Kazatchkine, and B Bellon, and S V Kaveri

[Intravenous immunoglobulin (IVIG)].

March 2009, Nihon rinsho. Japanese journal of clinical medicine,

M D Kazatchkine, and B Bellon, and S V Kaveri

[Synergistic action of penicillin and immunoglobulin for intravenous (IVIG) use].

January 1996, Medycyna doswiadczalna i mikrobiologia,

M D Kazatchkine, and B Bellon, and S V Kaveri

Mechanisms of action of intravenous immunoglobulin.

February 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis,

M D Kazatchkine, and B Bellon, and S V Kaveri

Use of intravenous immunoglobulin G (IVIG).

January 2006, Best practice & research. Clinical haematology,

M D Kazatchkine, and B Bellon, and S V Kaveri

Safety of intravenous immunoglobulin (IVIG) therapy.

March 2007, Autoimmunity reviews,

M D Kazatchkine, and B Bellon, and S V Kaveri

IVIG--mechanisms of action.

July 2003, Allergy,

M D Kazatchkine, and B Bellon, and S V Kaveri

Basic principles of intravenous immunoglobulin (IVIg) treatment.

September 2006, Journal of neurology,